IoM's Sheila Burke on the Drug Safety Climate
This article was originally published in RPM Report
Executive Summary
The chair of the Institute of Medicine drug safety committee, Sheila Burke, agreed to an interview with The RPM Report on about issues related to the Food & Drug Administration's approval process and the debate on Capitol Hill over proposed legislation. Here are excerpts of the conversation.
You may also be interested in...
Drug Safety in Post-FDAAA Era: An Epidemiologist's View
Bruce Psaty, longtime advocate of increased post-market safety controls for drugs, sees big challenges looming for FDA as it tries to adapt to the new authorities granted by the 2007 Food & Drug Administration Amendments Act. Psaty views the establishment of a large 100-million-life post-market surveillance system as a particularly daunting challenge.
Tone Deaf: FDA Commissioner Hits the Wrong Note
When Andrew von Eschenbach was coaxed to come over from NCI to lead FDA, he seemed like a perfect choice to right the ship and manage FDA through the final years of the Bush Administration. But, as the hoopla over Avandia shows, the ship is still taking on water. The commissioner’s tone and vision aren’t helping.
Tone Deaf: FDA Commissioner Hits the Wrong Note
When Andrew von Eschenbach was coaxed to come over from NCI to lead FDA, he seemed like a perfect choice to right the ship and manage FDA through the final years of the Bush Administration. But, as the hoopla over Avandia shows, the ship is still taking on water. The commissioner’s tone and vision aren’t helping.